Artiva Biotherapeutics (ARTV), a company developing cell-based therapies for cancer treatment, has filed for an initial public offering on Nasdaq.
The biotech group did not disclose the size and price of the intended deal. The company hopes to list its shares on Nasdaq under the symbol ARTV, according to its profile.
Goldman Sachs, Cowen, Wedbush PacGrow and Evercore ISI are acting as leaders.
Artiva’s primary drug candidate, AB-101, is currently in Phase 1/2 research. The product is being evaluated in combination with the drug rituximab for the treatment of non-Hodgkins lymphoma.
The company also has two other treatments in development, AB-201 for solid tumors and AB-202 for B-cell malignancies. Artiva hopes to apply for regulatory approval to begin clinical trials for AB-201 in the second half of this year and for AB-202 in 2023.
For a more in-depth look at Artiva, check out Contributor Donovan Jones SA “Artiva Biotherapeutics Aims for $100 Million in IPO”.